Glyco-biomarker CEA Detection Service

Glyco-biomarker CEA Detection Service

As a tumor glyco-biomarker, carcinoembryonic antigen (CEA) is an effective indicator of response to cancer therapy. CD BioGlyco has developed a variety of sensitive and effective CEA detection methods using advanced instrumentation platforms and expertise.


As one of the most common gastrointestinal cancers worldwide, gastric cancer kills millions of patients each year. The survival rate of gastric cancer is only 20-25%, which may be the result of advanced diagnosis to a certain degree. In addition to tumor node-metastasis (TNM) stage and treatment choices, there may be other factors that affect the prognosis of gastric cancer patients, such as genetic abnormalities and tumor behavior and differentiation. Therefore, the choice of treatment is of great importance for the prognosis of patients with gastric cancer.

In 1965, CEA was identified by Gold and Freedman and was observed to potentiate metastasis of colon carcinoma cells, its sialofucosylated glycoforms act as selectin ligands. CEA is produced in a high proportion of cancers in many other organs. CEA has a significant impact on tumor metastasis and may be associated with gastric cancer prognosis. CEA levels are elevated in gastric cancer patients, which is related to the survival of patients according to a systemic evaluation of serum markers for gastric cancer. Therefore, there is a need to develop a highly advanced technique for specific and sensitive CEA assays for clinical research and diagnosis.

The methodology  of CEA detection based on dsDNA-templated copper nanoparticles. Fig.1 The methodology of CEA detection based on dsDNA-templated copper nanoparticles. (Chen, 2018)

Our Strategies

CD BioGlyco has developed ultra-sensitive, simple and reliable strategies for the detection of glyco-biomarker CEA. The strategies we provide include but are not limited to:

  • We provide selective and sensitive analysis of CEA by a sandwich-type electrochemical aptasensor with electrocatalyst and nanocarrier (i.e. Pt/Au diaminonaphthalene (DN)-graphene).
  • We have constructed and tested a sandwich-type electrochemical immunosensor for CEA detection. In this method, a ferrocene derivative is integrated into the sensor design to detect CEA in buffers and biological samples and gold nanoparticles were used to increase the conductivity of the sensing surfaces.
  • We developed a simple method for CEA determination based on the binding of dsDNA-modeled copper nanoparticles (CuNPs) to an aptamer. The assay provides a sensitive and accurate determination of CEA and has been successfully used in biological samples.


  • Screening for gastric cancer
  • Function as diagnostic aids for cancer
  • Application in assessing prognosis
  • Detection of disease recurrence

Advantages of Us

  • Professional and standardized analysis
  • Simple pre-processing process
  • Time-saving analytical procedures
  • Highly accurate instrumentation

Knowing the details of CEA is helpful for doctors to make personalized treatment according to tumor characteristics. CD BioGlyco has developed multiple strategies for the detection of glyco-biomarker CEA. If you have a demand for glyco-biomarker detection services, please contact us for further information.


  1. Chen, M.; et al. A sensitive detection method of carcinoembryonic antigen based on dsDNA-templated copper nanoparticles. New Journal of Chemistry. 2018, 42(16): 13702-13707.
  2. Tao, Z. Electrochemical immune analysis system for gastric cancer biomarker carcinoembryonic antigen (CEA) detection. International journal of electrochemical science. 2018, 1413-1422.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.